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Abstract 
Background 
The 19 kDa C-terminal region of Plasmodium falciparum Merozoite Surface Protein-1 is a 
known target of naturally acquired humoral immunity and a malaria vaccine candidate. MSP-
119 has four predominant haplotypes resulting in amino acid changes labelled EKNG, QKNG, 
QTSR and ETSR. IgG antibodies directed against all four variants have been detected, but it 
is not known if these variant specific antibodies are associated with haplotype-specific 
protection from infection. 
Methods 
Blood samples from 201 healthy Kenyan adults and children who participated in a 12-week 
treatment time-to-infection study were evaluated. Venous blood drawn at baseline (week 0) 
was examined for functional and serologic antibodies to MSP-119 and MSP-142 variants. 
MSP-119 haplotypes were detected by a multiplex PCR assay at baseline and weekly 
throughout the study. Generalized linear models controlling for age, baseline MSP-119 
haplotype and parasite density were used to determine the relationship between infecting P. 
falciparum MSP-119 haplotype and variant-specific antibodies. 
Results 
A total of 964 infections resulting in 1,533 MSP-119 haplotypes detected were examined. The 
most common haplotypes were EKNG and QKNG, followed by ETSR and QTSR. Children 
had higher parasite densities, greater complexity of infection (>1 haplotype), and more 
frequent changes in haplotypes over time compared to adults. Infecting MSP-119 haplotype at 
baseline (week 0) had no influence on haplotypes detected over the subsequent 11 weeks 
among children or adults. Children but not adults with MSP-119 and some MSP-142 variant 
antibodies detected by serology at baseline had delayed time-to-infection. There was no 
significant association of variant-specific serology or functional antibodies at baseline with 
infecting haplotype at baseline or during 11 weeks of follow up among children or adults. 
Conclusions 
Variant transcending IgG antibodies to MSP-119 are associated with protection from infection 
in children, but not adults. These data suggest that inclusion of more than one MSP-119 
variant may not be required in a malaria blood stage vaccine. 
Keywords 
Plasmodium falciparum, Antibodies, Merozoite surface protein, Malaria infection, Children 
Background 
Merozoite Surface Protein-1 (MSP-1) is the most abundant protein found on the surface of 
blood stage Plasmodium falciparum merozoites, and has been considered a candidate for a 
blood stage malaria vaccine. The protein is expressed late in the blood stage cycle as a ~200 
kDa precursor protein attached to the merozoite surface via a C-terminal 
glycosylphosphatidylinositol anchor. Full-length MSP-1 undergoes primary proteolytic 
processing just prior to schizont rupture, to produce a complex of four MSP-1 fragments that 
remain non-covalently associated on the merozoite surface [1]. During merozoite invasion of 
the erythrocyte, a MSP-142 fragment is further processed to produce MSP-133 and MSP-119 
[1-3]. MSP-119 remains on the merozoite surface during invasion and is readily detectable in 
newly infected erythrocytes [2]. The Pfmsp1 gene can be divided into conserved, semi-
conserved and variable blocks based on comparisons of deduced amino acid sequences of 
various clones and field isolates [4]. Block 17 encodes MSP-119 that includes 98 highly 
conserved amino acids, with the exception of residues 1644 (E/Q), 1691(T/K), 1700 (S/N), 
and 1701 (R/G). Non-synonymous changes at these positions result in four predominant 
haplotypes: ETSR (PNG-MAD20 type), EKNG (Uganda-PA type), QKNG (Wellcome type), 
and QTSR (Indo type) [5-8]. 
MSP-119 is thought to play a role in erythrocyte invasion as naturally acquired antibodies 
directed against it can inhibit this process [9-11] and are associated with protection against 
malaria infection and disease [5,12-19]. However, it is unclear whether protective immune 
responses are MSP-119 variant-specific or if prior exposure to one infecting haplotype 
conveys cross protection from another haplotype. Some degree of cross protection has been 
demonstrated in experimental vaccine studies of P. falciparum challenged monkeys [20,21]. 
Determining the MSP-119 haplotype(s) present during naturally occurring infection is 
essential for assessment of MSP-1 vaccine efficacy and more generally, studies of variant 
transcending protective immunity in human populations. 
A phase 2 MSP-1 vaccine trial recently conducted in western Kenya showed no evidence of 
protective efficacy [22]. The vaccine contained 3D7 MSP-142, which includes the ETSR 
variant of MSP-119. However, the predominant haplotypes in this region have been reported 
to encode the EKNG and QKNG [23,24], underscoring the potential significance of 
understanding whether variant-specific immunity is operative. The current study reports the 
temporal stability of infecting MSP-119 haplotypes among individuals naturally infected with 
P. falciparum malaria in this area, and determines if changes in haplotype were affected by 
age, infection density, complexity of infection, and pre-existing variant-specific antibody 
responses. 
Methods 
Study population and design 
One hundred and one healthy adults (age range ≥18 to 79 years; average 39.6 years) and 100 
healthy children (age range one to 14 years; average 7.7 years) residing in the sub-location of 
Kanyawegi, Nyanza Province, Kenya were enrolled in a treatment time-to-infection study in 
July 2003. Malaria is holoendemic in this area, and transmission is relatively high in July. All 
study participants were afebrile and had normal age-adjusted haemoglobin levels. Venous 
blood samples were collected at baseline for immunologic and parasite genotyping studies. 
Witnessed age- and weight-appropriate six-dose regimens of Coartem® 
(artemether/lumefantrine) were given to all study participants at baseline regardless of 
malaria infection status determined by blood smear (BS). Weekly finger-prick blood samples 
were collected for 11 consecutive weeks after treatment. Ethical approval for the study was 
obtained from the Institutional Review Board for human investigations at University Hospital 
Case Medical Center and the Ethical Review Committee of the Kenya Medical Research 
Institute. Adult participants signed a written consent form in English or Duhluo (the local 
language); parents or guardians signed in the case of minors <15 years. 
Malaria diagnosis by blood smear 
Thick and thin BS were prepared, fixed in 100% methanol, stained with 5% Giemsa, and 
examined by light microscopy for P. falciparum-infected erythrocytes. A slide was deemed 
negative when no parasites were seen after counting microscopic fields containing at least 
200 leukocytes. The density of parasitaemia was expressed as the number of asexual P. 
falciparum/μL blood assuming a leukocyte count of 8,000/μL. 
MSP-119 haplotype detection by PCR/LDR-FMA 
DNA was extracted from 200 μL of venous blood and parasite cultures (3D7 = PNG-MAD20 
and K1 = Wellcome strains, as positive controls) using QIAamp DNA blood mini kit (Qiagen 
Corp, Valencia, CA, USA). PCR amplification was performed using MSP-119 specific and P. 
falciparum small subunit rRNA specific primers for 27 cycles (for quantification of parasite 
density) and 35 cycles (for determination of infection) as previously described [23]. The 
Ligase Detection Reaction – Fluorescent Microsphere Assay (LDR-FMA) was performed as 
previously described [23]. Briefly, 1 μL of PCR product (from either 27 or 35 cycle PCR) 
was ligased with four allele specific probes and two fluorescently labelled conserved 
sequence probes to detect the four possible haplotypes. Five μL of this LDR was then 
hybridized to ~250 Luminex® FlexMAP™ microspheres from each allelic set (total 
number = 5). Reporter streptavidin-R-phycoerythrin (Molecular Probes, Eugene, OR, USA) 
was added and detection of allele-specific LDR microsphere labelled hybrid complexes was 
performed using a BioPlex array reader (Bio-Rad Laboratories, Hercules, CA, USA). Each 
Luminex® fluorescent microsphere emits a unique fluorescent ―classification‖ signal across 
the range of 658–712 nm. ―Reporter‖ fluorescent signals from R-phycoerythrin are detected, 
classified into the allele-specific bins, and reported as median fluorescent intensity (MFI) by 
the BioPlex array reader and BioPlex Manager 3.0 software. Haplotype assignment was made 
based on allele-specific MFI as described [23]. Importantly, if four alleles (Q, E, KNG and 
TSR) were detected in a single sample, a conservative assumption was made that only two 
haplotypes were present. Therefore, the maximum number of haplotypes assigned to any 
infection was two. 
IgG antibodies to MSP-119 measured by ELISA 
IgG antibodies to recombinant PfMSP-119 corresponding to the EKNG, QKNG, ETSR and 
QTSR variants (expressed in Saccharomyces cerevisiae and provided by the Malaria 
Research and Reference Reagent Resource Center, Manassas, VA, USA [25]) were 
quantified by ELISA as described previously [26]. Briefly, Immulon 4 plates were coated 
with 0.1 μg/mL of each MSP-119 protein. Plasma samples from nine North American adults 
never exposed to malaria were used as the negative controls. Plasma pooled from four known 
malaria immune Kenyan adults was used to create a standard curve for each plate tested. The 
value obtained with a 1:50 dilution of the positive pool was designated as 100 arbitrary units 
(AU), 1:100 dilution as 50 AU, 1:200 dilution as 25 AU, 1:500 dilution as 10 AU, 1:1,000 
dilution 5 AU, and 1:2,000 dilution as 1 AU. A four-parameter standard fit curve was 
constructed from the positive control plasma pool and applied to sample values. Positive 
values were greater than the mean +3 SD of the value of the individual negative control 
plasma samples. 
IgG antibodies to MSP-142 measured by Luminex® multiplex assay 
Recombinant proteins expressed in Escherichia coli were kindly provided by Carole Long 
and Sanjay Singh (3D7/ETSR and FVO/QKNG) and David Narum (FUP/EKNG) (NIAID, 
Bethesda, MD, USA). Carboxylated microsperes (Luminex, Austin, TX, USA) were coupled 
to malaria antigens using the manufacturer’s protocol and as described [27,28]. Briefly, 0.5 
μg of recombinant MSP-142 protein was coupled to 6.1 x 10
5
 pre-activated microspheres in 
500 μL of 50 mM MES pH 5.0 coupling buffer, vortexed and incubated for two hours at 
room temperature. Microspheres were washed in PBS, 0.1% BSA, 0.02% Tween-20, 0.05% 
azide, pH 7.4 (blocking/storage buffer). Antigen-specific IgG was detected by incubating 
1,000 beads of each antigen per well with 1:100 plasma dilution in a final volume of 100 uL. 
After washing, detection with a 1:200 dilution of R-PE-conjugated goat F(ab’)2 anti-human 
IgG antibody (Jackson Immunoresearch, West Grove, PA, USA) was added. At least 75 
beads of each antigen were then acquired by the Bioplex reader (Bio-Rad, Hercules, CA, 
USA). Positive and negative controls were as described for MSP-119 ELISA. Results are 
expressed as MFI and positive values were assigned to samples with an MFI greater than the 
mean +3 SD of the value of the individual negative control plasma samples. 
MSP-119 invasion inhibitory antibodies (MSP-119 IIA) 
Methods to quantify MSP-119 IIA were as described previously [18,29,30]. Briefly, D10-
PfM3’ which encodes the MSP-119 MAD20/3D7/ETSR haplotype, and an isogenic D10-
PcMEGF parasite line in which the antigenically unrelated murine Plasmodium chabaudi 
orthologue replaces the Pf MSP-119 region were tested in parallel. Ring-stage parasites were 
synchronized twice by sorbitol lysis and allowed to mature to late trophozoite/schizont 
stages. Parasites were adjusted to 4% haematocrit with 0.5% P. falciparum-infected red cells, 
and 50 μL aliquots were placed in 96-well, flat-bottom microtiter plates with an equal volume 
of 1:5 prediluted plasma in culture medium (final plasma dilution 1:10, final volume 100 μL). 
The same batch of prediluted plasma was added to the two parasite lines in the same assay. 
The cultures were incubated for 26 hours to allow for schizont rupture and merozoite 
invasion. Twenty-five μL of resuspended cultures was removed, fixed with 0.25% 
gluteraldehyde in PBS for 45 minutes, and placed in 1 μg of Hoechst 33342 (HO) stain 
(Molecular Probes, Eugene, OR, USA) in 400 μL 1x PBS for >24 hours at 4 °C [29,31]. 
Stained cells were examined using the UV laser on a BD LSR II flow cytometer to collect 
data from a minimum of 5x10
4
 cells using Becton-Dickinson FACS Diva 5.01. Ring-stage 
parasitaemia was calculated by quantifying singly infected erythrocytes plus multiply 
infected erythrocytes (quantified as having two intracellular rings) according to flow 
cytometry gating previously described [31]. FlowJo 8.5.1 was used to analyse cytometry data. 
The mean number ring-stage parasitaemia for duplicate wells was calculated and results 
expressed as a percentage of the ring-stage parasitaemia of non-immune control plasma 
(derived from non-malaria exposed adults) in parallel cultures. The percentage change of 
invasion inhibition antibodies specifically attributable to anti-MSP-119 antibodies (MSP-119 
IIA) was calculated by subtracting the percentage of invasion of D10-PfM3’ relative to non-
immune controls from the percent invasion of D10-PcMEGF relative to non-immune 
controls. A positive response was defined as ≥10% inhibition attributable to MSP-119 IIA. 
Statistical analysis 
Parasite density was compared across groups using the Kruskal-Wallis test. Parasite 
haplotype distribution across groups was compared using chi square tests and generalized 
estimating equations. Generalized linear models with robust estimators and exchangeable 
correlation structure were used to characterize parasite density, frequency of parasite 
haplotype change over time, and relationship between antibody responses and infecting 
haplotypes over time. Time-to-infection was compared between baseline variant-specific 
antibodies (responders vs non responders and high levels vs low levels) using Kaplan-Meier 
curves, Wilcoxon and log rank tests. All statistical analysis was performed using Statistical 
Analysis Software (SAS®) version 9.2 (Cary, NC, USA). 
Results 
Analysis of haplotype prevalence, complexity of infection and parasite density was 
performed using data obtained from all 201 study participants. Data from 25 study 
participants who were BS negative but positive by the more sensitive PCR LDR-FMA for 
blood stage P. falciparum [23] two weeks after administration of Coartem were presumed to 
have liver stage infection at baseline. These 25 individuals (three adults and 22 children) 
were excluded from analyses which compared differences between baseline and follow-up 
haplotypes with respect to age, P. falciparum density, antibody responses, and time-to-
infection (n = 176 for these analyses). For clarity, the number of participants analysed is 
stated with the specific results. 
Prevalence and density of infection by BS and PCR/LDR-FMA (n = 201) 
Initial malaria prevalence in this population of healthy, asymptomatic individuals was 58% 
by BS and 57% by PCR/LDR-FMA (Figure 1A and 1B). The proportion of infected 
individuals by BS remained lower than week 0 (baseline) throughout the subsequent 11 
weekly blood samplings. In contrast, the proportion of infected individuals detected by 
PCR/LDR-FMA showed that baseline infection prevalence was reached after week 7 and 
stable thereafter. Parasite density was calculated for BS + and PCR/LDR-FMA + samples 
(Figure 1C and 1D). There was no statistical difference for parasite densities measured by BS 
after week 2 (weeks 3–11; Kruskal-Wallis test, p = 0.90). However, there was an increase in 
parasite densities after week 2 when measured by PCR/LDR-FMA (weeks 3–11; Kruskal-
Wallis test, p < 0.0001). This most likely reflects the increased sensitivity of PCR/LDR-FMA 
compared to microscopy. As expected, children at baseline had greater parasite densities than 
adults (3,740 vs 148 P. falciparum/μL by BS, p < 0.001; 6,325 vs 1,298 MFI by PCR/LDR-
FMA, p < 0.001 Kruskal-Wallis test). 
Figure 1 Prevalence and parasite density by blood smear (BS) and PCR/LDR-FMA. 
Panels A and B illustrate the proportion of study participants with infections measured by BS 
(A) and PCR/LDR-FMA (B) each week of the study. The parasite density (mean + SD) was 
calculated from infection positive samples as measured by BS (C) and PCR/LDR-FMA (D). 
No statistical difference was detected in BS parasite densities between weeks 3–11, but an 
increase in parasite densities measured by PCR/LDR-FMA was detected (weeks 3–11; 
Kruskal-Wallis test, p < 0.0001). The number of infected samples by BS by week: 0 (n = 116), 
1 (n = 0), 2 (n = 0), 3 (n = 10), 4 (n = 36), 5 (n = 61), 6 (n = 69), 7 (n = 80), 8 (n = 72), 9 (n = 79), 
10 (n = 75), 11 (n = 67). The number of infected samples by PCR/LDR-FMA by week: 0 
(n = 112), 1 (n = 39), 2 (n = 25), 3 (n = 52), 4 (n = 73), 5 (n = 81), 6 (n = 83), 7 (n = 99), 8 
(n = 85), 9 (n = 103), 10 (n = 118), 11 (n = 94) 
Complexity of infection (COI; n = 201) 
Block 17 of the Pfmsp1 gene has four alleles, E, Q, KNG, and TSR, four distinct haplotypes 
referred to as EKNG, QKNG, ETSR, and QTSR. The proportion of individuals each week 
that had two, three or four alleles was examined (Figure 2). As expected, when P. falciparum 
density was low because of recent drug elimination, the COI was diminished compared to 
baseline (before Coartem treatment), dropping from 60% to 24% of infections with two or 
more alleles. Baseline complexity levels were reached by week 5 and remained relatively 
stable throughout the remaining study period. Children tended to be infected with more 
alleles at any given week compared to adults (e g, 75% of children had >2 alleles at baseline 
vs 34% of adults, p < 0.001). 
Figure 2 Proportion of alleles in malaria infected samples reflecting complexity of 
infection. Baseline (week 0) distribution of allele frequencies was re-established by weeks 5 
(no statistical difference between baseline and week 5) 
Generalized estimating equations were used to model single vs multiple haplotypes over time 
according to 1) parasite density at baseline or first P. falciparum infection during follow-up; 
2) current parasite density; 3) prior (lagged) parasite density; 4) total number of infections 
within an individual; and, 5) age, while accounting for repeated observations. There was no 
predictive value found of baseline parasite density for COI. However, individuals with 
multiple haplotypes at baseline tended to have multiple haplotypes detected during the 
follow-up period (p = 0.001-0.081). Finally, children were 12.1 times more likely to have 
multiple haplotype infections compared to adults (95% CI 4.5-32.4; p < 0.001). 
Haplotype prevalence at baseline and follow-up (n = 201) 
Of all 964 P. falciparum + samples, the majority of individual haplotypes among a total 1,533 
was EKNG (n = 736) followed by QKNG (n = 517), ETSR (n = 148) and QTSR (n = 132). 
There were multiple haplotypes in 570 infections. 
For all subsequent analyses, ―no infection‖ and multiple haplotype combinations (such as 
EKNG/QKNG, EKNG/ETSR etc.) were included. Figure 3 illustrates the overall prevalence 
of each haplotype group at baseline and first-detected infection at weeks 3–11 (n = 176). No 
infection (43%) was most common at baseline followed by EKNG/QKNG (18%), EKNG 
(17%), EKNG/QTSR (8%), QKNG (6%), EKNG/ETSR (4%), ETSR (3%) and QKNG/ETSR 
(2%). Similarly, the most frequent haplotype first detected during follow-up was 
EKNG/QKNG (28%), EKNG (23%), QKNG (16%), no infection (16%), ETSR (7%), 
QKNG/ETSR (5%), EKNG/QTSR (3%), EKNG/ETSR (2%) and QTSR (1%). There were no 
statistical differences between the prevalence of baseline haplotypes and haplotypes detected 
during follow-up. The only significant difference was that the prevalence of ―no infections‖ 
was lower during the follow-up period compared to baseline (p < 0.001). 
Figure 3 Prevalence of haplotypes at baseline and the first detectable haplotype during 
the follow-up period for each study participant. Baseline prevalence is indicated by black 
columns and first follow-up period haplotype detected is indicated by grey columns. * 
indicates statistically significant difference (p < 0.001; Chi-square) between baseline and 
follow-up proportion of individuals with no infection 
Chi-squared analyses were stratified by adult vs child to compare baseline vs follow-up 
infecting haplotype groups (n = 176). In the follow-up period, 23% of adults had no infection 
whereas 6% of the children had no infection (p = 0.002). There was no difference in the 
frequency of the various haplotypes between adults and children found to be P. 
falciparum + during follow-up (Table 1). Haplotype(s) detected during follow-up were not 
affected by baseline haplotype(s). For example, of 57 individuals infected solely with EKNG 
at baseline, 37% were re-infected during follow up with EKNG, 30% with QKNG, 18% with 
EKNG/QKNG, 7% with ETSR, 2% with EKNG/QTSR (2%), and 7% were not re-infected. 
This pattern is similar to that seen in overall haplotype infections at baseline and during 
follow up. Similarly, of 75 individuals with no infection at baseline, 25% of infections 
detected during follow-up were EKNG, 25% QKNG, 15% EKNG/QKNG and 9% ETSR , 
and 25% had no infection 
Table 1 Follow-up period haplotype prevalence in children and adults with infections 
 EKNG QKNG ETSR QTSR 
Children 73% 56% 18% 3% 
Adults 60% 60% 16% 5% 
Haplotype change over time (n = 176) 
Generalized linear models were used to quantify haplotype stability according to baseline 
haplotype and parasite density, follow-up infection haplotype and parasite density, and age 
group. Table 2 describes the number of changes in haplotypes according to the number of 
infections experienced during follow up from weeks 3 through 11 (e g, change = 1 for an 
individual with a single EKNG haplotype infection at week 3 and a single QKNG haplotype 
at week 7). There was no predictive value found of parasite density or individual haplotype at 
baseline or during follow up for changes in haplotypes over time. Children had significantly 
more haplotype changes (94%) compared to adults (67%; p < 0.001). An average of 2.8 
haplotype changes was observed among children vs 1.3 among adults. 
Table 2 Stability of haplotypes detected during the follow-up period (weeks 3–11) 
 No Change 1 Changes 2 Changes 3 Changes 4 Changes 5 Changes 6 Changes 
2 Infections 20 (44%) 25 (56%)      
3 Infections 4 (15%) 4 (15%) 0     
4 Infections 3 (14%) 16 (59%) 3 (11%) 0    
5 Infections 1 (8%) 1(8%) 4 (33%) 4 (33%) 0   
6 Infections 0 2 (11%) 4 (22%) 5 (28%) 6 (33%) 1 (6%)  
7 Infections 1 (3%) 4 (11%) 4 (11%) 8 (23%) 8 (23%) 8 (23%) 2 (6%) 
Number of haplotype changes is displayed by number of infections detected. Individuals who 
had one or no infections detected during the follow-up period were excluded (n = 40). 
Baseline haplotype and time-to-infection (n = 176) 
Kaplan-Meier curves and log rank tests comparing individuals infected at baseline with any 
haplotype and time-to-infection (with any haplotype) found no differences. Additional 
analysis grouping those infected with the most prevalent haplotypes (EKNG and QKNG) vs 
less prevalent haplotypes (ETSR and QTSR) also did not demonstrate any difference in time-
to-infection (p = 0.37). Thus baseline haplotype infection had no observable effect on 
subsequent infecting haplotypes or time-to-infection. 
Baseline and follow-up haplotype and parasite density (n = 201) 
Haplotype prevalence by week is displayed in Figure 4A. Each haplotype’s prevalence is 
relatively stable throughout the study period. EKNG and QKNG exhibit some variability in 
weeks 4 and 5 as new infections were detected in the population. To visualize the relationship 
between haplotype and parasite density, each infecting haplotype was adjusted for parasite 
density (P. falciparum small subunit RNA MFI of the LDR-FMA) and totalled by week. If 
multiple haplotypes were present in a single infection, a proportional parasite density was 
attributed to each haplotype. For example, if an infection contained similar quantities of 
QKNG and EKNG determined by allele specific MFI, then 50% of the P. falciparum density 
(measured by P. falciparum small unit RNA MFI) was assigned to QKNG and 50% to 
EKNG. If an infection contained both QKNG and EKNG but the former was predominant, 
then 75% of the P. falciparum density was assigned to QKNG and 25% to EKNG [23]. 
Figure 4B displays these data and illustrates the gradual resurgence of predominant EKNG 
and QKNG haplotypes over time, while ETSR and QTSR haplotypes remained low and 
comparably stable. 
Figure 4 Haplotype prevalence and weighted density. Panel A illustrates prevalence of the 
four haplotypes in each week. Panel B illustrates the cumulative infecting P. falciparum 
density associated with each haplotype by week for the study population 
As previously stated, children had higher baseline parasite densities compared to adults. 
Individuals infected with multiple haplotypes at baseline tended to have higher parasite 
densities compared to individuals infected with single haplotypes at baseline (MFI 8,140 vs 
3,578, t = −4.76, p < 0.001; n = 176). Because children had higher parasite densities, they 
tended to have multiple haplotypes detected (see section regarding symptomatic malaria). 
However, no differences were observed in baseline parasitaemia according to individual 
baseline haplotype. During the follow-up period, parasite density remained greater in children 
than adults (4,106 vs 1,824, t = −2.65, p < 0.001). However, baseline haplotypes did not 
predict re-infection parasite density (in individuals who had both baseline and follow-up 
period infections). At the first time of re-infection, parasite density was consistently lower 
than at baseline. The amount of decrease, however, was not related to the baseline density 
(R
2 = 0.03). 
Individuals with multiple haplotype infections during the follow-up period had greater 
parasite density compared to individuals with single haplotype infections. QKNG/ETSR, 
EKNG/ETSR or EKNG/QTSR infections had significantly greater density (MFI range 4,704-
8,879) compared to EKNG/QKNG, QKNG, EKNG, ETSR, and QTSR (MFI 572–3,216) 
(p < 0.001, ANOVA). Using these estimates of parasite density in a generalized linear model 
controlling for 1) baseline haplotype and density; 2) follow-up infection haplotype and 
density; and, 3) age, it was found that age and haplotype complexity remained predictors of 
parasite density (p = 0.081 and 0.024, respectively). Specifically, follow-up infections 
containing QKNG/ETSR resulted in greatest parasite densities (mean MFI 9,521), but this 
was not significantly different from the other combination haplotypes (EKNG/ETSR or 
EKNG/QTSR) exhibiting greater densities than single haplotype infections. With these data, 
parasite density over time was then examined. Longitudinal models were created to estimate 
parasite density after first infection during follow up. It was found that the parasite density 
was unstable and did not follow an observable trend; there was poor model fit. 
Relationship between baseline variant-specific antibody responses, haplotype-
specific infections, and time-to-infection (n = 176) 
IgG antibodies directed against MSP-119 (EKNG, QKNG, ETSR, and QTSR) and MSP-142 
(EKNG, QKNG, and ETSR) were measured by ELISA and Luminex® multiplex assay using 
plasma samples obtained at baseline. Additionally, functional MSP-119 IIA (ETSR) was 
measured. No plasma samples were available from the follow-up period. There was no 
correlation between MSP-119 IIA (ETSR only) and antibodies to MSP-142 (ETSR; 
kappa = 0.0131) or MSP-119 (ETSR; R
2 = 0.0147) measured by serology, as previously 
demonstrated [18,32]. 
Figure 5A and 5B illustrate the proportion of serologically measured variant-specific 
antibody responders to recombinant MSP-119 and MSP-142. First, how many variants an 
individual responded to was examined. Interestingly, many participants had no detectable 
variant-specific antibodies (approximately 40% and 60% of participants did not respond to 
MSP-119 or MSP-142). There were no statistical differences in percent responders detected 
between adults and children or between responders with antibodies to multiple variants vs no 
variants. With regard to the frequency of variant-specific responses among those individuals 
who were responders, there was no statistical difference detected among variants of MSP-119 
and MSP-142 or between adults and children (Figure 6A and 6B). The results were consistent 
whether antibodies against MSP-119 variants were measured by ELISA or antibodies against 
MSP-142 variants were measured by Luminex® multiplex assay. 
Figure 5 Distribution of variant-specific antibody responders for MSP-119 and MSP-142 
at baseline. All responders (black columns), adults (grey columns) and children (white 
columns) frequencies are displayed for either MSP-119 variants (panel A) or MSP-142 variants 
(panel B). Note that MSP-142 QTSR was not tested, thus the maximum number of antigens 
participants could respond to is three. No statistical difference between frequency of adult 
and children was detected for any group 
Figure 6 Distribution of variant-specific antibody responders for MSP-119 and MSP-142 
at baseline stratified by variant. All responders (black columns), adults (grey columns) and 
children (white columns) frequencies are displayed for either MSP-119 variants (panel A) or 
MSP-142 variants (panel B). MSP-142 QTSR was not examined. No statistical difference 
between prevalence in adult and children was detected for any variant 
Children had a shorter time-to-infection compared to adults, presumably due to less well 
developed clinical immunity (average week of infection for children was 5.3 (BS) and 2.5 
(PCR/LDR-FMA) vs adults 7.4 (BS) and 5.0 (PCR/LDR-FMA)). Children who were MSP-
119 variants responders at baseline had a delayed time-to-infection as measured by BS 
compared to children with non-responders (Figure 7). Children with high-level antibodies 
(upper tercile) to MSP-142 FUP/EKNG (wilcoxan test p = 0.035; log-rank p = 0.057) or upper 
two tercile antibodies to MSP-142 FVO/QKNG (log-rank p = 0.0324), had delayed time-to-
infection as measured by BS, whereas those with upper tercile antibodies to MSP-142 
3D7/ETSR demonstrated no statistically significant delay to infection (log-rank p = 0.3760). 
Adults with antibodies to MSP-119 or MSP-142 variants had no delay in time-to-infection 
compared to non-responders. When time-to-infection was measured by PCR/LDR-FMA, 
similar trends were observed but statistically significant delays in time-to-infection were only 
observed in children responders to MSP-119 ETSR (log-rank p = 0.0223) and QTSR (log-rank 
p = 0.0350) but not QKNG (log-rank p = 0.0617) or EKNG log-rank (p = 0.3692). Children 
with antibodies to MSP-142 FUP/EKNG (log-rank p = 0.0143) but not 3D7/ETSR (log-rank 
p = 0.8) or FVO/QKNG (log-rank p = 0.1) had delayed time-to-infection compared to children 
with no variant-specific antibodies. Adults with antibodies to MSP-119 or MSP-142 variants 
had no delay in time-to-infection compared to non-responders. Children with antibodies to 
multiple variants had no difference in time-to-infection compared with children with 
antibodies to one variant. No change in time-to-infection (measured by BS or PCR/LDR-
FMA) as related to MSP119 IIA (ETSR) responses was observed in children or adults. 
Figure 7 Kaplan-Meier curves illustrating delay in time-to-infection for children with 
MSP-119 variant-specific antibodies at baseline. The four Kaplan-Meier curves show the 
percent of children remaining malaria infection free (measured by BS) on the Y axis over 
time (weeks of follow up, X axis) stratified by whether the children had MSP-119 variant-
specific antibodies (EKNG, QKNG, ETSR or QTSR) at baseline (week 0). Children with 
antibodies (responders) are represented with a dashed red line, and those with no antibodies 
are represented with a solid blue line. Children with antibodies against the MSP-119 variants 
had a delayed time-to-infection compared to those with no antibodies 
One of the goals was to determine if variant-specific antibodies to the C-terminal 19 kDa 
region of MSP-1 present at baseline were predictive of protection from subsequent haplotype-
specific infection. 176 participants were characterized as responders or non-responders for 
serologic responses to each antigen tested at baseline. Chi-squared tests for univariate 
analysis did not demonstrate any significant relationships between baseline variant-specific 
serology or functional antibodies and baseline or follow-up infection haplotypes. Logistic 
regressions controlling for age, baseline haplotype and parasite density also did not reveal 
any significant associations between baseline variant-specific serology or functional 
antibodies and infecting haplotypes (baseline or follow-up period infections). Variant-specific 
antibodies did not have a protective or detrimental effect on subsequent haplotype-specific 
infection (or lack of infection). In summary, children with variant-specific MSP-119 
antibodies demonstrated delayed time-to-infection, but follow-up infection haplotype bore no 
relationship to baseline MSP-119 variant-specific antibodies. 
Characteristics of participants who developed symptomatic uncomplicated 
malaria infections during the follow-up period 
During the 11 weeks of follow up after baseline Coartem administration, 18 individuals 
developed febrile malaria infections (axillary temperature >37.8 °C and parasitaemia) 
requiring retreatment with CoArtem®. Seventeen individuals were children (mean age 7.3 
years, range 2.1-11.5 years). Six of these 18 individuals had no infection at baseline. The 
predominant haplotypes at baseline of the other 12 individuals were EKNG (four), 
EKNG/QKNG (five), and EKNG/ETSR (three), which is a haplotype prevalence similar to 
that observed in the general population. At the time of symptomatic infection, five 
individuals were infected with EKNG/QKNG haplotypes, five with EKNG/QTSR, two with 
EKNG, and one individual for each of the remaining haplotypes (EKNG, QKNG/ETSR, 
QKNG/QTSR, EKNG/ETSR, ETSR, QTSR). This haplotype frequency again reflects the 
general population haplotype distribution during the follow-up period. All symptomatic 
individuals had asymptomatic infections prior to malarial disease (minimum one week prior, 
maximum seven weeks). Fifteen had detectable infections one to two weeks after CoArtem® 
retreatment (measured by PCR/LDR-FMA), but the parasite densities were lower compared 
to parasite densities associated with symptoms. Five individuals had a decrease in detectable 
parasite density for one to two weeks after medication, but then an increase in parasite 
density in the subsequent weeks (an example is shown in Figure 8A). Nine symptomatic 
individuals had new haplotypes detected one to two weeks prior to symptoms (an example is 
shown in Figure 8B). Nine study participants had all haplotypes present at some point during 
the follow-up period (an example is shown in Figure 8C). With respect to the presence or 
magnitude of antibody responses of these symptomatic individuals, no statistical difference 
was detected between this group and those who did not have disease or age-matched 
asymptomatic individuals. Of note, none of the symptomatic individuals had any MSP-119 
IIA detectable at baseline compared to 6% of the general population (p = 0.6; exact test). Over 
the entire follow-up period, 17 symptomatic individuals had more than one haplotype present 
in their infections, with an average of 3.04 different haplotypes during the follow-up period 
compared to 2.72 among age-matched, asymptomatic individuals (p = 0.185). Symptomatic 
individuals tended to have higher P. falciparum densities at baseline and during the follow-up 
period compared to age-matched, asymptomatic individuals, but this was not statistically 
significant (p = 0.08 and p = 0.67, respectively). 
Figure 8 Examples of detected infections for three symptomatic children over the study 
period demonstrating P. falciparum density and haplotypes detected. The red arrow 
denotes the week each child developed symptomatic clinical malaria and was retreated with 
Coartem®. The X axis denotes the week of the study and the Y axis denotes P. falciparum 
density by MFI. In Panel A, P. falciparum infection was detected several weeks prior to 
symptoms. With low parasitaemia, only a single haplotype (EKNG) was detected. It may be 
that amplifying the Q allele was below the threshold of detection with low parasitaemia. In 
Panel B, Coartem® administration was followed by a rapid decline of detectable 
parasitaemia, but increases in parasitaemia were seen in weeks 7–9. Panel C shows infections 
in weeks 3–6 with ENKG/QKNG haplotypes. In week 7, a new haplotype QTSR was 
detected prior to the development of clinical malaria 
Discussion 
Antigenic polymorphism is considered a significant confounder in the development of 
antibody-mediated protection against blood stage P. falciparum in the context of naturally 
acquired immunity and malaria vaccine development. The goal of this study was to determine 
whether variant-specific antibodies to MSP-119 were associated with haplotype-specific 
protection in a cohort of Kenyan adults and children who participated in a treatment time-to-
infection study. These data showed that i) baseline infecting MSP-119 haplotype had no effect 
on the subsequent infecting haplotypes; ii) variant-specific IgG antibodies measured 
serologically and functionally had no association with follow-up infecting haplotypes or 
density; iii) variant-specific antibodies correlated with delayed time-to-infection among 
children but not adults; and, iv) variant-specific antibodies were associated with protection in 
a haplotype-transcending manner. Considered together, these data found no evidence for 
haplotype-specific immunity to MSP-119 in this study of naturally infected individuals living 
in a malaria holoendemic region. 
EKNG and QKNG were the most prevalent MSP-119 haplotypes in this population and region 
of western Kenya in 2003 when this study was conducted. From other surveys, it has been 
found that this distribution of MSP-119 haplotype distribution pattern is stable (Yeo, 
unpublished). Takala et al. found comparable results with EKNG and QKNG being the most 
prevalent haplotypes in Mali from 1999 to 2001 [33]. Others have shown similar dominances 
of EKNG and QKNG in Kenya, Brazil, Vietnam, Thailand, Tanzania and Vanuatu [24,34-
36]. 
It was found that within a single individual, infecting haplotypes frequently changed from 
week to week. This could be due in part to sampling effect. A finger-prick blood sample does 
not accurately reflect total body haplotype prevalence or parasitaemia. Additionally, this 
study showed that with low parasitaemia haplotype detection may not be optimal (Figure 8). 
In several studies, parasite densities and parasite genotypes varied significantly within a 24-
hour time period and over days to weeks [37-40]. Furthermore, venous blood may reflect 
different densities than finger-prick blood as the latter would be expected to have a greater 
frequency of capillary-sequestered infected erythrocytes. Examining weekly infections may 
heighten the variability detected, but with repeated measures in 176 participants over a 12-
week study period, overall trends should persist. To this end, it was found that haplotype 
complexity was associated with P. falciparum density and possibly symptomatic infections. 
This contrasts with others’ finding that complexity of infection was associated with increased 
age and decreased frequency of symptomatic infection [33]. An important point in this regard 
is that children had higher parasite densities than adults, and this most likely led to better 
detection of multiple haplotypes. 
Analysis of serologic responses was performed using recombinant MSP-119 (four variants) 
and MSP-142 (three variants). Variability in protein folding and expression systems used to 
produce these products, e g, yeast and E. coli, and serology techniques (traditional ELISA vs 
Luminex® multiplex) could account for differences in determining antibody responders vs 
non-responders. Nevertheless, these data indicated that both approaches produced a similar 
overall result — no discernible variant-specific immune correlation, consistent with the 
notion that variant-specific antibodies cross react with heterologous variants. Using 
immunodepletion assays, Zakeri et al. found evidence of antibody cross-reactivity among 
several MSP-119 variants, consistent with these findings [36]. 
A significant limitation to the approach of detecting the infecting haplotype is the assumption 
made to assign two haplotypes to an infection that contained all four alleles. Although in 
most cases a predominant haplotype could be differentiated from a minor haplotype with the 
MFI of each detected allele, it is not certain that only two haplotypes were present [23]. For 
example, if an infection composed of all four alleles had higher MFIs for Q > E and 
KNG > TSR, the haplotypes would be assigned as QKNG and ETSR. However, it is possible 
that the individual was actually infected with QKNG, EKNG and ETSR. The only way to 
definitively determine this would be to have a larger blood volume and clone and sequence 
multiple PCR products, an approach which was not feasible for this study. Other methods 
such as pyrosequencing are advantageous in that direct sequencing of amplicons is possible. 
This study had limited power to detect associations between antibody responses and infecting 
haplotypes in the context of susceptibility to symptomatic malaria. The 18 individuals who 
developed clinical malaria during the follow-up period did not have a discernible variant-
specific antibody pattern. They did, however, lack MSP-119 IIA antibodies, which has 
previously been shown to increase with haplotype-specific (ETSR) infection [29]. 
Interestingly, 15 of these symptomatic individuals had P. falciparum detectable by PCR at 
least one week after treatment. Although this study was not designed to examine the efficacy 
of Coartem® treatment, previous observations demonstrate that parasites are cleared from the 
blood within 48 hours [41]. Although the possibility that detection of P. falciparum after 
treatment resulted from residual P. falciparum DNA cannot be excluded, it is most likely that 
detection resulted from the progression of pre-existing liver stage P. falciparum to the blood 
stage as Coartem® does not eliminate the former. Inadequate adherence to treatment regimen 
and/or lack of food intake with medication consumption could also result in incomplete 
parasite clearance [42,43], but is unlikely with this study as all six doses of Coartem were 
directly observed by project staff. All but one participant with symptomatic malaria during 
the follow-up period had infections containing three or more MSP-119 alleles. Increased COI 
may be associated with increased risk of symptomatic malaria, as has been observed 
previously [44,45]. Malaria transmission intensity and seasonality may also affect COI, but 
this study was not designed or powered to detect this association. 
Conclusion 
Healthy asymptomatic children and adults living in a holoendemic malaria region displayed 
no MSP-119 variant-specific antibody protection (measured serologically or functionally) 
against haplotype-specific infections regardless of age or parasite density (baseline or follow-
up infection). The infecting haplotype frequency reflected the population haplotype 
prevalence even after drug clearance. There was no discernible relationship between variant-
specific antibody responses and haplotype-specific infections. Variant-specific antibody 
responses and occurrence of malaria disease was not evaluated in this study but needs to be 
addressed in order to better inform vaccine development. 
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